Trial · NCT02636088
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
NCT02636088, Phase 2, Unknown, Gabriella Alexandersson von Döbeln
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer. Trials, record NCT02636088. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02636088
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
- NCT number
- NCT02636088
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 51 participants, actual
- Lead sponsor
- Gabriella Alexandersson von Döbeln
- Conditions
- Esophageal Neoplasm
- Interventions
- Cetuximab
- First posted
- 2015-12-21
- Last updated
- 2018-09-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Local tumour Control | 1 year | Local tumour control will be measured with a computed tomography |
| Secondary | Progression-free survival | 3 years | Tumour respons evaluation with CT-scan |
| Secondary | Toxicity | 3 years | Toxicity will be measured with the Common Toxicity Criteria Scale |
| Secondary | Patterns of relapse | 3 years | First site of recurrence will be evaluated with CT, supplemented with biopsy if indicated |
| Secondary | Overall and disease-free survival | 3 years | Tumour respons evaluation with CT scan |
| Secondary | Quality of life | 3 years | Quality of life assessed with the EORTC QLQ-C30 questionnaire. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02636088
GET https://conductscience.org/api/trials/v1/NCT02636088/registered